ASX Health Stocks: BOD says all trials are done, and it’s time to begin commercialising Aqua Phase
Health & Biotech
Health & Biotech
Link copied to
Cannabis focused biotech, Bod Science (ASX:BOD), surged 12% this morning after providing further update on the development work to support the commercialisation of its Aqua Phase technology.
Bod has now completed two PK studies to demonstrate the enhanced bioavailability of CBD when used with the Aqua Phase technology, compared with CBD in MCT oil.
After completing the second PK study, BOD says the Aqua Phase CBD PK trial results have demonstrated six times greater bioavailability than CBD in oil.
Data from the two PK studies have demonstrated consistent results, although significantly increased bioavailability was seen in the initial venous study in July.
These results have now officially brought Bod’s research and development work to support the commercialisation of the Aqua Phase technology to a successful end.
“We are pleased with the results from this second PK study as they further support the exciting properties of Aqua Phase as a unique product delivery process technology. The results verify the value proposition,” said BOD CEO, Joe Patterson.
Aqua Phase is a product delivery process technology that solves solubility and bioavailability limitations with drugs that are poorly absorbed by the body through oral dose formats.
Whilst Aqua Phase has significant application within the cannabis sector it is agnostic in its application and offers a much broader opportunity. Bod says it can be used across cannabis, pharmaceutical, nutraceuticals and beverage.
“Aqua Phase holds a broader opportunity for drugs that have solubility and bioavailability limitation, not being limited to the cannabis sector,” said Patterson.
Meanwhile, ImpediMed (ASX:IPD) has announced the appointment of Steven Chen as chief medical officer.
Dr Chen is a board-certified surgical oncologist who brings extensive leadership experience in cancer care.
He was previously the chief medical officer of cancer biotech company Avelas Bioscience, and chief of Breast Surgery at the University of California Davis Medical Center.
He has published over 70 publications and 5,000 citations.
Dr Chen says this is an exciting time to join ImpediMed as the company drives the commercialisation of its bioimpedance spectroscopy technology as standard of care for cancer patients.